Skip to main content
. 2022 Nov 23;78(1):71–83. doi: 10.1111/all.15571

TABLE 1.

Characteristics of the included studies

Author (all 2021) Country Design Female % Age Number of 1st dose reactions evaluated a Number who received 2nd dose Number of 1st dose immediate reactions skin tested Number not skin tested Reason not skin tested Skin tested and received 2nd dose 2nd dose deferred Reason 2nd dose deferred 2nd dose anaphylaxis Included patients with anaphylaxis to 1st dose (n tested) Graded dosing Premedication allowed Tested to vaccine g Tested to excipient g
Tuong et al. 18 US Case series 100

42.8 y

(21–64 y)

 15 15 11 4 Patients declined testing 11 0 NA 2 b

Yes

(n = 1)

 Yes No

Yes

(both)

Yes

(both)
Krantz et al. 19 US, Denmark Case series 100

44.8 y

(29–54 y)

 8 8 8 0 NA 8 0 NA 0

Yes

(n = 4)

 No Yes No

Yes

(both)
Rassmussen et al. 20 Denmark Case series 88.5

46 y

(18–88 y)

 16 16 16 0 NA 16 0 NA 0

Yes

(n = 4)

 No No

Yes

(Pfizer)

Yes

(PEG)
Wolfson et al. 21 US Case series 89

40.9 y

(sd 13.6)

 65 58 65 0 NA 58 7 2 PEG+ and 5 PEG‐ skin test patients declined 3 c

Yes

(n = 3)

 No Yes No

Yes

(both)
Kessel et al. 22 Israel Case series 77.8

54.3 y

(23–75 y)

 18 18 16 2 Not specified 16 0 0

Yes

(n = 7)

 No Yes

Yes

(Pfizer)

Yes

(PEG)
Kelso et al. 23 US Case report 100

48.6 y

(43–56 y)

 4 3 4 0 NA 3 1 Skin test ‐ patient declined because of fear of needing epinephrine 0

Yes

(n = 3)

 No No

Yes

(Pfizer)

 No
Mustafa et al. 24 US Case report 100 64 y, 39 y 2 2 2 0 NA 2 0 NA 0 No Yes No

Yes

(Moderna)

Yes

(both)
Vanijcharoenkarn et al. 25 US Case series 92 Not specified 88 73 16 72 Investigators stopped testing after the first 16 patients due to utility. 16 15 9 deferred without explanation, 6 lost to follow up. None were tested 0

Yes

(n = 4)

 Yes No No

Yes

(both)
Park et al. 26 US Case report 100 34 y 1 1 1 0 NA 1 0 NA 0

Yes

(n = 1)

 No No

Yes

(Pfizer)

Yes

(PEG)
Loli‐Ausejo et al. 27 Spain Case series 81.8

39 y

(29.5–56.5)

 6 6 6 0 NA 6 0 NA 0 No Yes Yes

Yes

(Pfizer)

Yes

(PEG)
Pitlick et al. 28 US Case series 80

48 y

(20–90 y)

 41 41 41 0 NA 41 d 0 NA 0

Yes

(n = 4)

 Yes No

Yes

(both)

Yes

(both)

Kohli‐Pamnani

et al.  29

US Case series 87 56 y (sd 16) 18 16 18 0 NA 16 2 2 skin test negative patients preferred to receive Janssen vaccine. 0

Yes

(n = 1)

 No yes

Yes

(both)

Yes

(both)
Warren et al. 30 US Case series 91

40.9 y

(sd 10.3)

 22 11 11 11 Patients declined testing 11 d 11 Not stated 1 e

Yes

(n = 11)

 No No

Yes

(both)

Yes

(both)
Carpenter et al. 31 US Case report 100 60 y 2 1 2 0 Received Janssen vaccine 1 1 A skin test negative patient preferred to receive the Janssen vaccine 0 No No No No

Yes

(both)
Kaplan et al. 32 US Case series 86.7

48 y

(19–89 y)

 34 27 31 3 The investigators stopped testing 27 4 3 patients with +PS testing were lost to follow up; 1 patient with ‐PS testing deferred 0

Yes

(N = 1)

 Yes Yes No

Yes

(both)
AlMuhizi et al. 33 Canada Case series 86.9

55 y

(43.25–65 y)

 40 40 29 0 NA 40 0 NA 0

Yes

(n = 15)

 Yes No

Yes f

(Pfizer)

Yes

(both)

Van Meerbeke

et al. 34

US Case Series 80

50.2 y

(31–59)

 8 8 8 0 NA 8 0 NA 0

Yes

(n = 4)

 Yes Yes

Yes

(both)

Yes

(both)
Otani et al. 35 US Case Series 89

45 y

(24–78 y)

 42 42 14 28 The investigators stopped testing 14 0 NA 2

Yes

(n = 6)

 No No No

Yes

(both)
Csuth et al. 36 Sweden Case Series 80.9

45 y

(16–90 y)

 21 20 21 0 NA 20 1 1 skin test negative patient declined. Had received epinephrine with first dose but did not meet Brighton Level 1–3 criteria 0

Yes

(n = 7)

 No No No

Yes

(PEG)
Cahil and Kan 37 Canada Case Report 100

44 y

(35, 52 y)

 2 2 2 0 NA 2 0 NA 0

Yes

(n = 2)

 Yes Yes

Yes

(Pfizer)

Yes

(PEG)
a

Column represents the total number of 1st dose reactions that were evaluated in the study. Not all of these patients underwent skin testing, re‐vaccination, or both. Thus, some patients met our selection criteria, and some were vaccinated without testing.

b

Both cases of anaphylaxis occurred on the last step of a multi‐dose desensitization, and one of these patients was sensitized to the Moderna vaccine but negative to the excipients. Neither had 1st dose anaphylaxis.

c

All 3 anaphylaxis cases had both anaphylaxis to their first dose and negative skin testing to the excipients prior to the 2nd dose.

d

Totals supplemented by author personal communication, which account for additional vaccination of persons who initially deferred vaccination after testing at the time of initial publication.

e

Patient had anaphylaxis to both the first and second dose, with positive skin testing to vaccine (Pfizer) but negative skin testing to the excipients prior to 2nd dose.

f

Only a single patient was tested to vaccine (Pfizer) in this study.

g

Indicates which vaccine or excipient was used for testing in persons who met inclusion criteria and were re‐vaccinated.